Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL1731

View Full Paper
Ask AI
Bookmark
Share

Authors

RRRachel E. RauACAndrew J. CarrollSCSusan J. Conway

Discussion

Loading...

Member takes

Overview

Randomised trial improved disease-free survival in children with B-acute lymphoblastic leukemia, suggesting blinatumomab's positive impact on prognostic factors.

Key Points

  • To evaluate the efficacy of blinatumomab in improving disease-free survival in children with standard risk B-acute lymphoblastic leukemia.
  • COG Trial AALL1731 was conducted with newly diagnosed NCI standard risk B-ALL patients.
  • Participants were randomized to receive standard chemotherapy or chemotherapy plus blinatumomab.
  • Patients were risk stratified based on minimal residual disease and other prognostic factors.
  • Interim analyses compared disease-free survival between the treatment arms.
  • Adding blinatumomab significantly improved 4-year disease-free survival to 94.8% compared to 86.9% in control arms.
  • The cumulative incidence of relapse was lower for blinatumomab recipients at 4.4% compared to 12.6% in controls.
  • Hispanic ethnicity showed reduced prognostic impact in the blinatumomab groups.
  • Certain adverse genetic factors still impacted outcomes but blinatumomab retained effectiveness across subgroups.

Cite This Study

Rau et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d063https://doi.org/10.1182/blood-2025-758
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials2025
  2. 2T-cell engaging bispecific antibody shows potent MRD negativity with variable remission and survival outcomes: A bayesian meta-analysis of randomized controlled trials2025
  3. 3Safety and efficacy of consolidation-Phase blinatumomab in newly diagnosed B-cell acute lymphoblastic leukemia : A systematic review and meta-analysis2025
  4. 4Blinatumomab before and after allogeneic hematopoietic stem cell transplantation in adult patients with B-cell acute lymphoblastic leukemia2025
  5. 5Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher2025